Inform Genomics, Tesaro to Assess Risk of Chemotherapy Side Effects | GenomeWeb

NEW YORK (GenomeWeb News) – Inform Genomics said today it has reached a deal with Tesaro to evaluate the risk of chemotherapy-induced nausea and vomiting in patients.

Using Inform Genomics' bioinformatics and genomic platforms, Tesaro will assess the risk of nausea and vomiting in patients receiving certain "moderately" emetogenic chemotherapy regimens and standard antiemetic therapy, without an NK-1 receptor antagonist, Inform said.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.